BMY - Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
As of May 15, 2026: spot at $56.98, ATM IV 25.9%, max pain $57.50, net GEX $11.1M.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market Cap
- $115.15B
- P/E Ratio
- 15.84
- Beta
- 0.26
- 52-Week Range
- 42.52-62.89
- Dividend Yield
- $2.50
- CEO
- Christopher S. Boerner
- Employees
- 34,100
- IPO Date
- Jun 1, 1972
- Exchange
- NYSE
What BMY Looks Like to Options Traders Today
IV rank of 28.7% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($11.1M) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.012) is roughly flat across the wings.
What This Page Covers
The BMY overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked BMY overview questions
- What is BMY?
- BMY is the ticker symbol for Bristol-Myers Squibb Company, a listed security. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. Listed on NYSE. BMY is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the BMY options snapshot look like today?
- As of May 15, 2026, the BMY options snapshot shows spot at $56.98, ATM IV 25.9%, IV rank 28.7%, max pain $57.50, net GEX $11.1M, expected move 7.43%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are BMY's key statistics?
- Bristol-Myers Squibb Company (BMY) carries a market capitalization of $115.15B, trailing P/E ratio of 15.84, beta of 0.26 relative to the broader market, 52-week range of 42.52-62.89. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does BMY belong to?
- Bristol-Myers Squibb Company operates in the Healthcare sector, in the Drug Manufacturers - General industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare BMY's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the BMY data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).